D-Sight is a spin-off company from Vall d’Hebron Institute of Research (VHIR) lead by an experienced and committed team dedicated to the discovery and development of new innovative treatments for neurodegenerative diseases of the retina.
We are shaping the future of retinal diseases treatment with our first product in development: a first-in-class eye drop formulation for the prevention and treatment of diabetic retinopathy in its early stages.
D-Sight's mission is to improve the quality of life of diabetic patients by providing new innovative therapeutic solutions for the several complications arising from the neurodegeneration associated with this disease.
D-Sight is committed to promoting longevity with a sustained sense of well-being, improving health and aging‐related outcomes worldwide. We aim to provide medical solutions for the growing global health burden due to chronic diseases, such as diabetes.
Changing the way you age